Kimura Yutaka, Iijima Shouhei, Kato Takeshi, Tsujie Masaki, Naoi Yasuto, Hayashi Taro, Tanigawa Takahiko, Yamamoto Hitoshi, Kurokawa Eiji, Kikkawa Nobuteru, Matsuura Nariaki
Gastrointestinal Research Center, Dept. of Surgery, Minoh City Hospital.
Gan To Kagaku Ryoho. 2003 Aug;30(8):1125-30.
The quality of life (QOL) of patients with advanced or recurrent gastric cancer is poor and their immunocompetence is low, making it important to conduct chemotherapy while at the same time improving their QOL and maintaining their immunocompetence. To improve QOL and increase compliance by reducing the side effects but not the antitumor effect of TS-1, a 2-week regime with 2-week administration of TS-1, and a 1-week drug-free interval in combination with the immunotherapeutic agent lentinan (LNT) was started in 5 patients with advanced or recurrent gastric cancer. Toxicity, efficacy, QOL, and immunological parameters were investigated preliminarily to examine whether or not usefulness of lentinan could be evaluated. QOL scores for appetite, nausea/vomiting, and abdominal pain/diarrhea showed improvement, although not in statistically significant values. The Th2 (CD4-positive, IL4-positive T cells) response in peripheral blood decreased significantly. TS-1 and lentinan combination immunotherapy was carried out safely with advanced recurrent gastric cancer. In order to examine the usefulness of LNT combined use, it was thought that a randomised trial using toxicity with not only efficacy but QOL and immunological parameters as indicators would be beneficial.
晚期或复发性胃癌患者的生活质量（QOL）较差，免疫能力较低，因此在进行化疗的同时提高其生活质量并维持免疫能力非常重要。为了通过减少替吉奥（TS-1）的副作用而非抗肿瘤作用来提高生活质量并增加依从性，对5例晚期或复发性胃癌患者开始采用一种为期2周的方案，即每2周服用TS-1，并结合免疫治疗药物香菇多糖（LNT）设置1周的无药间隔期。对毒性、疗效、生活质量和免疫参数进行了初步研究，以检验香菇多糖的有效性是否可以评估。食欲、恶心/呕吐和腹痛/腹泻的生活质量评分有所改善，尽管未达到统计学显著水平。外周血中的Th2（CD4阳性、IL4阳性T细胞）反应显著降低。TS-1与香菇多糖联合免疫疗法在晚期复发性胃癌患者中安全实施。为了检验香菇多糖联合使用的有效性，认为以毒性、疗效、生活质量和免疫参数作为指标进行随机试验将是有益的。
